Market Newsdesk

DUBAI, United Arab Emirates and NEW YORK, Aug. 22, 2026 (GLOBE NEWSWIRE) — SuperiorMed Holdings Limited, a Cayman Islands company (“SuperiorMed” or the “Company”), a company that shall become the parent company of SuperiorMed Healthcare Management FZ-LLC, a company in the business of management and consulting service for certain medical institutions under the laws of the United Arab Emirates (“UAE”), announced today that it has entered into an Agreement and Plan of Merger (the “Merger Agreement”) on August 22, 2026 for a business combination with Starry Sea Acquisition Corp (Nasdaq: SSEA, SSEAU, SSEAR), a special purpose acquisition company incorporated in the Cayman Islands (“SSEA”).

Upon consummation of the transaction contemplated by the Merger Agreement, (i) SSEA will be merged with and into SuperiorMed Healthcare Group (the “Purchaser”), a Cayman Islands exempted company and wholly-owned subsidiary of SSEA (the “SPAC Merger”), and (ii) concurrently with the SPAC Merger, SuperiorMed Healthcare MergerCo, a Cayman Islands exempted company and wholly-owned subsidiary of the Purchaser (the “Merger Sub”), will be merged with and into SuperiorMed, resulting in SuperiorMed being a wholly owned subsidiary of the Purchaser (the “Business Combination” and the transactions in connection with the Business Combination collectively, the “Transaction”). Upon the closing of the Transaction, the Purchaser is expected to be a publicly traded company.

SuperiorMed Holdings Limited Overview

SuperiorMed Holdings Limited is a Cayman-incorporated holding company and the parent company of a Dubai-based healthcare management and services platform, with its core business focused on longevity medicine, wellness services, and health tourism services. Through its Dubai-based operating subsidiary, SuperiorMed Healthcare Management FZ-LLC, which in turn owns two UAE operating subsidiaries, one of which operates an additional branch, the Company has established an integrated service suite encompassing clinic and wellness facility management, associated clinical operations, patient referral coordination, health tourism facilitation through hotel-integrated retreat programs, as well as the management and operation of clinic and wellness projects.

Key Transaction Terms

Under the terms of the Merger Agreement, SSEA will merge with and into Purchaser, its wholly owned subsidiary, which Purchaser surviving the SPAC Merger and becoming the publicly listed company, and its wholly owned subsidiary, Merger Sub, will merge with and into SuperiorMed, with SuperiorMed being the surviving company with the end result being Purchaser as the publicly listed company, in each case subject to the terms and conditions of the Agreement. At the effective time of the Transaction, SuperiorMed’s shareholders will receive ordinary shares of the Purchaser. The ordinary shares held by certain SuperiorMed shareholders will be subject to lock-up agreements for a period of 180 days following the closing of the Transaction, subject to certain exceptions. Upon closing of the Business Combination, the security holders of SSEA will be entitled to receive ordinary shares of the Purchaser.

The Transaction, which has been approved by both SSEA and SuperiorMed’s board of directors, is subject to regulatory approvals, the approvals by the shareholders of SSEA and SuperiorMed, respectively, as well as the satisfaction of certain other customary closing conditions, including, among others, a registration statement, of which the proxy statement/prospectus forms a part, being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), and the approval by the stock exchange of the listing application of the combined company.

The description of the Business Combination contained herein is only a summary and is qualified in its entirety by reference to the Merger Agreement relating to the Business Combination. A more detailed description of the Transaction and a copy of the Merger Agreement will be included in a Current Report on Form 8-K to be filed by SSEA with the SEC and will be available on the SEC’s website at www.sec.gov.

Advisors

Loeb & Loeb LLP, Hogan Lovells International LLP, and Ogier are serving as legal advisors to SuperiorMed. Torres & Zheng at Law, P.C., GLA & Company Ltd, and Harney Westwood & Riegels, are serving as legal advisors to SSEA.

About SuperiorMed Holdings Limited

SuperiorMed Holdings Limited is a Cayman-incorporated holding company and the parent company of a Dubai-based healthcare management and services platform, with its core business focused on longevity medicine, wellness services, and health tourism services. Through its Dubai-based operating subsidiary, SuperiorMed Healthcare Management FZ-LLC, which in turn owns two UAE operating subsidiaries, one of which operates an additional branch, the Company has established an integrated service suite encompassing clinic and wellness facility management, associated clinical operations, patient referral coordination, health tourism facilitation through hotel-integrated retreat programs, as well as the management and operation of clinic and wellness projects.

About
Starry Sea Acquisition Corp

Starry Sea Acquisition Corp is a blank check company formed under the laws of the Cayman Islands for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Participants in the Solicitation

SuperiorMed, SSEA, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of SSEA’s ordinary shares in respect of the proposed Transaction. Information about SSEA’s directors and executive officers and their ownership of SSEA’s ordinary shares is currently set forth in SSEA’s prospectus related to its initial public offering dated August 7, 2025, filed with the SEC on August 8, 2025, as modified or supplemented by its Annual Report on the Form 10-K for the fiscal year ended December 31, 2025 and any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation will be included in a registration statement on Form S-4 or F-4 (as may be amended from time to time) that will include a proxy statement and a registration statement/preliminary prospectus (the “Registration Statement”) pertaining to the proposed Transaction when it becomes available. These documents can be obtained free of charge from the sources indicated below.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction and does not constitute an offer to sell or the solicitation of an offer to buy any securities of SSEA or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Important Information about the Proposed Business Combination and Where to Find It

In connection with the Transaction, the Purchaser will file relevant materials with the SEC, including the Registration Statement. Promptly after the Registration Statement is declared effective, the proxy statement/prospectus will be sent to all SSEA shareholders entitled to vote at the special meeting relating to the Transaction. Before making any voting decision, the securities holders of SSEA are urged to read the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the Transaction as they become available because they will contain important information about the Transaction and the parties to the Transaction.

Stockholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed or that will be filed with the SEC through SSEA through the website maintained by the SEC at www.sec.gov, or by directing a request to the contacts mentioned below.

Yan Liang
Chief Executive Officer and Director
Starry Sea Acquisition Corp
Tel: (646) 750-8895

SuperiorMed Holdings Limited
Director
Christopher Robin Axelsson
Email: [email protected]

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. SSEA’s and SuperiorMed’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, SSEA’s and SuperiorMed’s expectations with respect to future performance and anticipated financial impacts of the Business Combination, the satisfaction of the closing conditions to the Business Combination and the timing of the completion of the Business Combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of SSEA and SuperiorMed and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed Business Combination; (2) the outcome of any legal proceedings that may be instituted against SSEA and SuperiorMed following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the Business Combination, including due to failure to obtain approval of the shareholders of SSEA or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company’s ordinary shares on Nasdaq following the Business Combination; (7) the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; (8) the ability to realize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the Business Combination; (10) changes in applicable laws or regulations; (11) the possibility that SuperiorMed or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Registration Statement filed by the Purchaser (when available) relating to the Business Combination, including those under “Risk Factors” therein, and in other filings with the SEC made by SSEA and SuperiorMed. SSEA and SuperiorMed caution that the foregoing list of factors is not exclusive. SSEA and SuperiorMed caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither SSEA and SuperiorMed undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AEVEX Corp. (NYSE: AVEX): (i) Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with AEVEX’ April 2026 initial public offering (“IPO”); and/or (ii) publicly traded Class A common stock between April 17, 2026 and June 4, 2026, inclusive (the “Class Period”), have until October 20, 2026 to seek appointment as lead plaintiff of the AEVEX class action lawsuit. Captioned Rosenberg v. AEVEX Corp., No. 26-cv-04779 (S.D. Cal.), the AEVEX class action lawsuit charges AEVEX, Madison Dearborn Partners, LLC, AEVEX’ controlling private equity owner, and certain of AEVEX’ top executives, directors, and underwriters of the IPO with violations of the Securities Act of 1933 and/or the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

AEVEX

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-aevex-corp-class-action-lawsuit-avex.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert

of Robbins Geller by calling 800/851-7783 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: AEVEX operates as a defense technology contractor and enabler of the U.S. Unmanned Aerial Systems (UAS) dominance strategy mission. AEVEX operates in two segments, Tactical Systems and Global Solutions. The complaint alleges that in its April 2026 IPO, AEVEX sold 18.4 million shares of common stock.

The AEVEX class action lawsuit alleges that in the IPO’s offering documents and throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that despite conveying a commitment to follow a 180-day “lock-up” and therefore prevent Madison Dearborn Partners, LLC from selling its Class A common stock or converting or exchanging its Class B or LLC Units into Class A common stock for public sale until at least October 13, 2026, defendants concealed a pre-arranged plan between Madison Dearborn Partners, LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Jefferies LLC to prematurely abrogate that commitment and allow for a secondary public offering (“SPO”) shortly after the IPO.

On June 1, 2026, after the market closed, AEVEX allegedly filed a registration statement with the SEC on Form S-1 announcing AEVEX’ intention to sell eight million more shares of Class A common stock to the investing public via an SPO. On this news, the price of Aevex Class A common stock fell approximately 16%, according to the complaint.

On June 5, 2026, AEVEX filed a final prospectus, dated June 3, 2026, with the SEC on Form 424B4, which, together with the registration statement, formed the offering documents for the SPO. The offering documents for the SPO allegedly disclosed the existence of the defendants’ pre-arranged plan to waive Madison Dearborn Partners, LLC’s “lock-up” restrictions. On this news, the price of Aevex Class A common stock fell 7% further, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired AEVEX Class A common stock pursuant and/or traceable to the IPO’s offering documents and/or during the Class Period to seek appointment as lead plaintiff in the AEVEX class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the AEVEX investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the AEVEX shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the AEVEX class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
            Robbins Geller Rudman & Dowd LLP
            Ken Dolitsky
            Michael Albert
            655 W. Broadway, Suite 1900, San Diego, CA 92101
            800/851-7783
            [email protected]

PHILADELPHIA, Aug. 21, 2026 (GLOBE NEWSWIRE) — Brandywine Realty Trust (NYSE:BDN) announced today the expiration of the previously announced cash tender offer (the “2028 Notes Tender Offer”) by its operating partnership, Brandywine Operating Partnership, LP (the “Operating Partnership”), for up to $50,000,000 in aggregate principal amount (the “2028 Series Cap”) of its outstanding 7.550% guaranteed notes due 2028 (the “2028 Notes”). The Operating Partnership previously announced that it had extended its cash tender offer (the “2029 Notes Tender Offer” and, together with the 2028 Notes Tender Offer, the “Tender Offers”) for its outstanding 8.875% guaranteed notes due 2029 (the “2029 Notes” and, together with the 2028 Notes, the “Notes”) and increased the aggregate principal amount applicable to the 2029 Notes that it would accept (the “2029 Series Cap”) from $50,000,000 to $70,000,000, resulting in a corresponding increase in the aggregate maximum tender amount (the “Aggregate Maximum Tender Amount”) from $100,000,000 to $120,000,000. The 2028 Notes Tender Offer expired at 5:00 p.m., New York City time, on Friday, August 21, 2026 (the “2028 Notes Expiration Date”) pursuant to the Operating Partnership’s Offer to Purchase, dated August 17, 2026 (the “Offer to Purchase”). As of the 2028 Notes Expiration Date, $327,405,000 or approximately 93.5% of the $350,000,000 aggregate principal amount of the 2028 Notes had been validly tendered and not withdrawn in the 2028 Notes Tender Offer. The Operating Partnership accepted for purchase $50,000,000 of the 2028 Notes validly tendered and delivered (and not validly withdrawn) in the 2028 Notes Tender Offer at or prior to the 2028 Notes Expiration Date, subject to the 2028 Series Cap and proration. The 2029 Notes Tender Offer remains open and its expiration date has been extended to 5:00 p.m., New York City time, on August 27, 2026. Payment for the 2028 Notes purchased pursuant to the 2028 Notes Tender Offer is intended to be made on August 25, 2026 (the “2028 Notes Settlement Date”).

Certain information regarding the 2028 Notes is set forth in the table below.

(1) As of the date of this press release, as a result of downgrades in our senior unsecured credit ratings since the date of issuance of the 2028 Notes, the interest rate on the 2028 Notes has increased an aggregate of 75 bps to 8.30% due to the coupon adjustment provisions in the 2028 Notes.

(2) No representation is made as to the correctness or accuracy of the CUSIP Numbers listed in this press release. They are provided solely for the convenience of the Holders (as defined herein) of the Notes.

(3) As of the date of this press release.

The 2028 Notes validly tendered will be subject to a proration factor of approximately 15.3%, with appropriate adjustments downward to the nearest $1,000 principal amount to avoid the purchases of the 2028 Notes in principal amounts other than in integral multiples of $1,000. Because the 2029 Notes Tender Offer remains open, no proration factor for the 2029 Notes can be determined at this time; any proration factor for the 2029 Notes will be determined following expiration of the extended 2029 Notes Tender Offer.

The consideration to be paid under the Tender Offers will be $1,047.50 per $1,000 principal amount of 2028 Notes and $1,068.75 per $1,000 principal amount of 2029 Notes (the “Tender Offer Consideration”), plus accrued and unpaid interest to, but not including, the applicable Settlement Date. Payment for the 2028 Notes accepted for purchase in the 2028 Notes Tender Offer is expected to be made on the 2028 Notes Settlement Date. The 2029 Notes Tender Offer remains open, and payment for 2029 Notes accepted for purchase is expected to be made on August 27, 2026. The Tender Offer Consideration and accrued and unpaid interest will be funded with cash on hand and/or borrowings under the $600,000,000 line of credit under the Operating Partnership’s Second Amended and Restated Credit Agreement.

It is expected that the Operating Partnership will retire approximately 14.3% of the aggregate principal amount outstanding of the 2028 Notes pursuant to the 2028 Notes Tender Offer. The results of the 2029 Notes Tender Offer, including the percentage of the 2029 Notes retired, will be announced following expiration of the extended 2029 Notes Tender Offer.

The Tender Offers were made pursuant to the Offer to Purchase. BofA Securities, Inc. acted as the Dealer Manager (as defined in the Offer to Purchase) and Citizens JMP Securities, LLC, M&T Securities, Inc., Truist Securities, Inc. and Wells Fargo Securities, LLC acted as Joint Dealer Managers for the Tender Offers. This press release is neither an offer to purchase nor a solicitation to buy any of the Notes nor is it a solicitation for acceptance of the Tender Offers.

About Brandywine Realty Trust

Brandywine Realty Trust (NYSE: BDN) is one of the largest, publicly traded, full-service, integrated real estate companies in the United States with a core focus in Philadelphia, PA and Austin, TX. Organized as a real estate investment trust (REIT), we own, develop, lease and manage an urban, town center and transit-oriented portfolio comprising 112 properties and 19.2 million square feet as of June 30, 2026. Our purpose is to shape, connect and inspire the world around us through our expertise, the relationships we foster, the communities in which we live and work, and the history we build together. For more information, please visit www.brandywinerealty.com. 

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “1995 Act”) provides a “safe harbor” for forward-looking statements. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe-harbor provisions of the 1995 Act. Such forward-looking statements can generally be identified by our use of forward-looking terminology such as “will,” “strategy,” “expects,” “seeks,” “believes,” “potential,” or other similar words. Because such statements involve known and unknown risks, uncertainties and contingencies, actual results may differ materially from the expectations, intentions, beliefs, plans or predictions of the future expressed or implied by such forward-looking statements. These forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and not within our control. Factors that might cause actual results to differ materially from our expectations are set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2025. Accordingly, we caution readers not to place undue reliance on forward-looking statements. We assume no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.

Company / Investor Contact:

Tom Wirth
EVP & CFO
610-832-7434
[email protected]

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company“), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate update.

The Company announces the grant of an aggregate of 572,500 stock options (the “Stock Options“) to certain directors, officers, employees and consultants of the Company. Each Stock Option is exercisable at a price of C$4.80 for a period of five years from the date of grant, expiring on August 20, 2031. Of the Stock Options, 172,500 vested immediately upon grant, and the remaining 400,000 Stock Options are subject to performance-based vesting conditions.

The Stock Options and the common shares underlying the Stock Options are subject to a statutory four month and one day hold period. All Stock Options were granted in accordance with the Company’s omnibus equity incentive plan approved by shareholders on June 29, 2023.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid“), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd“) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Forward Looking Information

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to the vesting of the performance-based Stock Options and the satisfaction of the conditions thereto.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: risks relating to the Company’s business and operations generally; and the reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Contacts:

Quantum BioPharma Ltd.

Email: [email protected]
Telephone: (833) 571-1811